Ameriprise Financial Inc. Makes New $344,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Ameriprise Financial Inc. bought a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,544 shares of the company's stock, valued at approximately $344,000.

Several other large investors also recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock valued at $213,514,000 after acquiring an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after acquiring an additional 650,000 shares in the last quarter. Boxer Capital Management LLC purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at $17,098,000. Price T Rowe Associates Inc. MD lifted its position in shares of Kymera Therapeutics by 3.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock valued at $276,395,000 after acquiring an additional 224,859 shares in the last quarter. Finally, Foresite Capital Management VI LLC purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at $5,887,000.

Analysts Set New Price Targets

KYMR has been the topic of several recent research reports. Guggenheim restated a "buy" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. UBS Group reduced their price objective on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. JPMorgan Chase & Co. upped their price objective on Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, June 3rd. B. Riley upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the stock from $38.00 to $60.00 in a research report on Tuesday, June 3rd. Finally, Citigroup assumed coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 target price on the stock. Two analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $59.82.

Insider Activity

In other news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the sale, the chief executive officer now owns 660,482 shares in the company, valued at approximately $32,363,618. This trade represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 6,349 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $311,101.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Trading Down 1.0%

NASDAQ:KYMR traded down $0.46 on Monday, hitting $47.16. 847,867 shares of the stock were exchanged, compared to its average volume of 613,673. The stock has a market cap of $3.07 billion, a PE ratio of -20.15 and a beta of 2.07. The stock has a fifty day moving average of $30.67 and a 200-day moving average of $35.68. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm's revenue was up 114.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.69) earnings per share. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.